<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494832</url>
  </required_header>
  <id_info>
    <org_study_id>31416-A</org_study_id>
    <secondary_id>064705 A01</secondary_id>
    <nct_id>NCT00494832</nct_id>
  </id_info>
  <brief_title>Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery</brief_title>
  <official_title>Influence of Dexmedetomidine on the Evoked Potentials During Spine Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:&#xD;
&#xD;
        1. To evaluate the safety and efficacy of Dexmedetomidine as an adjunct for anesthesia&#xD;
           during spine surgery and&#xD;
&#xD;
        2. To investigate the influence of Dexmedetomidine on the evoked potentials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of evoked potentials can significantly improve neurologic outcome after major spine&#xD;
      surgery. Modalities of evoked potentials commonly used are Somato-Sensory Evoked Potentials&#xD;
      (SSEP's), Motor Evoked Potentials (MEP's), and Visual Evoked Potentials (VEP's).&#xD;
&#xD;
      Dexmedetomidine (DEX) is an alpha-2 agonist and has been FDA approved as an adjunct sedative&#xD;
      agent to general anesthesia. It has been purported to reduce the amount of anesthetic&#xD;
      required and potentiate the analgesic effect of opiates. In addition, DEX was shown to have&#xD;
      minimal effect on SSEP's and VEP's in both rats and humans. Any decrease in the dose of&#xD;
      general anesthesia that improves the monitoring of evoked potentials, supports DEX as an&#xD;
      adjunct.&#xD;
&#xD;
      It is known that all anesthetic agents can interfere with the recording of evoked potentials.&#xD;
      The choice of anesthetic however, depends on the modality of neurophysiologic monitoring&#xD;
      planned for the patient. Total intravenous anesthesia (TIVA) and Sevoflurane, a low dose&#xD;
      inhalational anesthetic are the usual agents for spine surgery. Both have a dose-related&#xD;
      depressant effect on the quality of evoked potentials. As a result, it is common practice for&#xD;
      the anesthesiologist to adjust the depth of anesthesia to improve signaling. The use of&#xD;
      either anesthetic must accompany continuous infusion of Propofol and an opioid, Remifentanil&#xD;
      or Fentanyl. The anesthesiologist then decides whether DEX should be as an adjunct. In our&#xD;
      experience, DEX did not impair evoked potentials. In fact, it improved the quality of signals&#xD;
      in a few patients. Yet, there are no published data of such effects in medical literature.&#xD;
&#xD;
      We hypothesize that Dexmedetomidine will not influence evoked potentials when used as an&#xD;
      adjunct to general anesthesia. Our study is prospective, randomized, double-blinded and will&#xD;
      be carried out on a set of anesthetics. We will first evaluate DEX as an adjunct in TIVA,&#xD;
      then as an adjunct to Sevoflurane. The probable benefit of DEX may avoid the use of potent&#xD;
      inhaled anesthetics which would improve VEP's monitoring. Quality recording of evoked&#xD;
      potentials can enhance our ability to detect iatrogenic injury to the spinal cord and vision.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in evoked potentials</measure>
    <time_frame>Duration of surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Spine Surgery</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>10 minutes loading dose of 0.9 mcg/kg&#xD;
Maintenance dose of 0.6 mcg/kg/hour</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Dexmedetomidine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>10 minutes loading dose of 0.9 mcg/kg&#xD;
Maintenance dose of 0.6 mcg/kg/hour</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0.9% Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult spine surgery patients requiring evoked potentials monitoring.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age younger than 18 and older than 80 years&#xD;
&#xD;
          -  Patients with moderate neurological deficit&#xD;
&#xD;
          -  ASA grade above 3&#xD;
&#xD;
          -  Any chronic psychiatric disorder&#xD;
&#xD;
          -  Body mass index (BMI) above 35&#xD;
&#xD;
          -  Patients with cortical blindness, cataracts, retinal or optic neuropathy, glaucoma,&#xD;
             untreated diabetes, active hepatitis, active coronary artery disease, untreated&#xD;
             arrhythmias and patients with renal or hepatic insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Rozet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Evoked potentials</keyword>
  <keyword>Spine surgery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

